Trials / Completed
CompletedNCT02423200
Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD
A Randomized, Open-Label, Multiple Dose Clinical Pharmacology Study of Two Doses of a Selective p38 MAP Kinase Inhibitor, VX-745 in Patients With Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) or With Mild AD
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- EIP Pharma Inc · Industry
- Sex
- All
- Age
- 60 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the effects of VX-745 on markers of disease in the central nervous system of patients with MCI due to AD or with mild AD. The study will also evaluate the safety and tolerability of VX-745 in these patients during 6 weeks of dosing, as well as the plasma and cerebrospinal fluid concentrations of VX-745 during dosing.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VX-745 | Orally-active P38 MAP kinase alpha-selective inhibitor |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2016-09-01
- Completion
- 2016-11-01
- First posted
- 2015-04-22
- Last updated
- 2018-04-03
- Results posted
- 2018-04-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02423200. Inclusion in this directory is not an endorsement.